Synthaverse S.A. (WSE:SVE)

Market Cap	271.76M -20.6%
Revenue (ttm)	71.76M +22.4%
Net Income	7.55M +58.7%
EPS	n/a
Shares Out	70.77M
PE Ratio	60.82
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	79,438
Average Volume	33,930
Open	3.870
Previous Close	3.840
Day's Range	3.860 - 3.950
52-Week Range	3.505 - 5.910
Beta	0.27
RSI	58.66
Earnings Date	Apr 29, 2026

About Synthaverse

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anty-D 50 and GAMMA anty-D 150, which are human anti-rh0(d) immunoglobulin products used in the prevention of maternal-fetal conflict in terms of the D antigen...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1944
• Employees: 239
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: SVE

Financial Performance

In 2024, Synthaverse's revenue was 71.76 million, an increase of 22.44% compared to the previous year's 58.61 million. Earnings were 7.55 million, an increase of 58.68%.